Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo

NCT01670032 is registered in ClinicalTrials.gov with NovaBay Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01670032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01670032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2012
Completion date
August 31, 2013
Enrollment
328 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

impetigo